Researchers identified three subtypes of amyotrophic lateral sclerosis, each with distinct mechanisms that could be future ...

Northwestern University professor Hande Ozdinler is hoping to change how ALS is treated, saying the disease is too complex ...

Amyotrophic lateral sclerosis may involve an autoimmune component — a finding that could reshape treatment strategies and ...

“Blessed are the peacemakers,” Trump wrote on social media. Well, they sure are, Mr. President, and now that you have brought ...

SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® ...

Neurizon is gearing up to begin its HEALEY ALS platform trial later this year after the FDA lifted a clinical hold on its ...

ALS may be linked to the immune system, which could explain differences in survival and open doors for new treatments.

While the overall trial did not meet its primary and secondary endpoints, Neuronata-R ® showed meaningful efficacy in patients with slower disease progression. These findings confirm Neuronata-R ® 's ...

Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17 ...

While the overall trial did not meet its primary and secondary endpoints, Neuronata-R ® showed meaningful efficacy in patients with slower disease progression. At 12 months, participants in this ...